← Back to Search

Other

AT193 for Hidradenitis Suppurativa

Phase 1
Waitlist Available
Research Sponsored by Azora Therapeutics Australia Pty Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate AT193 in approximately 44 participants with HS. The treatment period will be 8 weeks followed by a 2-week nontreatment follow-up. The primary objective of this study is to evaluate the safety and tolerability of AT193. The secondary objectives of this study are to evaluate the preliminary efficacy in the treatment of HS.

Eligible Conditions
  • Hidradenitis Suppurativa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of treatment-emergent adverse events

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AT193Experimental Treatment1 Intervention
Topical applied daily
Group II: PlaceboPlacebo Group1 Intervention
Topical applied daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AT193
2021
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Azora Therapeutics Australia Pty LtdLead Sponsor
1 Previous Clinical Trials
34 Total Patients Enrolled
~14 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top